Precigen, Inc. (NASDAQ:PGEN) Shares Bought by CIBC Private Wealth Group LLC

CIBC Private Wealth Group LLC increased its position in Precigen, Inc. (NASDAQ:PGEN) by 29.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 331,476 shares of the biotechnology company’s stock after acquiring an additional 74,422 shares during the period. CIBC Private Wealth Group LLC owned approximately 0.11% of Precigen worth $391,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of PGEN. Stifel Financial Corp grew its holdings in Precigen by 94.9% in the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 15,680 shares during the last quarter. SG Americas Securities LLC raised its position in Precigen by 27.9% during the fourth quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 12,578 shares during the last quarter. Stoneridge Investment Partners LLC raised its position in Precigen by 21.3% during the fourth quarter. Stoneridge Investment Partners LLC now owns 68,681 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 12,063 shares during the last quarter. Synovus Financial Corp lifted its holdings in shares of Precigen by 100.0% in the third quarter. Synovus Financial Corp now owns 98,130 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 49,065 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Precigen by 190.4% in the third quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 124,141 shares during the last quarter. 33.51% of the stock is owned by hedge funds and other institutional investors.

Precigen Stock Performance

PGEN stock opened at $1.24 on Friday. The company has a 50 day moving average price of $1.68 and a two-hundred day moving average price of $1.19. The stock has a market capitalization of $364.61 million, a P/E ratio of -2.25 and a beta of 1.58. Precigen, Inc. has a one year low of $0.65 and a one year high of $2.17.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. The business had revenue of $1.19 million during the quarter, compared to the consensus estimate of $1.30 million. Research analysts forecast that Precigen, Inc. will post -0.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PGEN has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Precigen in a research note on Thursday, March 20th. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research note on Tuesday, January 14th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $7.00.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.